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ABSTRACT  
 
Gray platelet syndrome is named after the gray appearance of platelets due to absence 
of alpha(α )-granules. It is caused by recessive mutations in NBEAL2, resulting in 
macrothrombocytopenia and myelofibrosis. Though using the term gray platelets for GATA1 
deficiency has been debated, a reduced number of α -granules has been described for 
macrothrombocytopenia due to GATA1 mutations. We compared platelet size and number of 
α-granules for two NBEAL2 and two GATA1 deficient patients and found reduced numbers 
of α-granules for all, with the defect being more pronounced for NBEAL2 deficiency. We 
further hypothesized that the granule defect for GATA1 is due to a defective control of 
NBEAL2 expression. Remarkably, platelets from two patients and GATA1-deficient mice 
express almost no NBEAL2. The differentiation of GATA1 patient-derived CD34+ stem cells 
to megakaryocytes showed defective proplatelet and α -granule formation with strongly 
reduced NBEAL2 protein and RNA expression. ChIP sequencing revealed 5 GATA binding 
sites in a regulatory region 31 kb upstream of NBEAL2 covered by an H3K4Me1 mark 
indicative of an enhancer locus. Luciferase reporter constructs containing this region 
confirmed its enhancer activity in K562 cells and mutagenesis of the GATA1 binding sites 
resulted in significantly reduced enhancer activity. Moreover, DNA binding studies showed 
that GATA1 and GATA2 physically interact with this enhancer region. GATA1 depletion 
using siRNA in K562 cells also resulted in reduced NBEAL2 expression. In conclusion, we 
here show a long-distance regulatory region with GATA1 binding sites as strong enhancer for 
NBEAL2 expression.  
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INTRODUCTION  
 
Platelets play a critical role in hemostasis and contain secretory granules that are 
essential to maintain their normal function. Of the three types of granules (dense, alpha and 
lysosomes), alpha (α)-granules are the most abundant type that store essential proteins for 
platelet adhesion and blood coagulation.1 Platelets are shed into the blood stream after the 
formation of long cytoplasmic extensions from differentiated megakaryocytes (MK), a 
process called proplatelet formation. The α-granules are formed in the early MK and are 
actively transported along microtubules from the MK cell body towards the proplatelets.1 In 
circulating platelets, these α-granules mature further and proteins will be actively or passively 
taken up from the plasma by receptor-mediated endocytosis in addition to the proteins loaded 
in these granules during their biosynthesis in the MK.2 Recently, it has become clear that α-
granule proteins play important roles in non-hemostatic events such as wound healing, cancer, 
inflammation and innate immunity.3 
Gray platelet syndrome (GPS, MIM139090) is a rare inherited platelet disorder 
characterized by mild to moderate bleeding, macrothrombocytopenia and markedly reduced 
or absent α-granules that typically results in a grayish appearance of platelets under the light 
microscope.4 Using three independent next generation sequencing approaches, recessive 
mutations in NBEAL2 were found to cause GPS.5-7 NBEAL2 encodes a 2.754 amino acid 
polypeptide, neurobeachin-like-2, that contains BEACH (named after Beige and Chediak-
Higashi), ARM (Armadillo), Con A-like lectin (Concanavalin A-like lectin domain), PH (PH-
domain like) and WD40 domains. The exact role of BEACH domain-containing proteins 
remains largely unknown but they are generally large proteins that are able to control diverse 
cellular mechanisms such as vesicular transport, apoptosis, membrane dynamics and receptor 
signaling.8 Interestingly, LYST and NBEA, two other BEACH domain-containing proteins, 
have been shown to be implicated in platelet dense-granule defects.9-10 Also for these proteins 
their exact contribution in granule formation and trafficking during MK and platelet formation 
remains unknown.  
In addition, the term GPS has been used for macrothrombocytopenia patients with 
defects in the X-linked GATA111 (MIM305371) or having an autosomal dominant loss of 
function variant in GFI1B12 (MIM187900). Both genes encode for transcription factors that 
regulate megakaryopoiesis and defects result in enlarged platelets with fewer (though not 
absent) α-granules as studied in additional GATA1 and GFI1B patients illustrated.13-18 Based 
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on a recent detailed comparison of clinical and laboratory data for NBEAL2, GATA1 and 
GFI1B patients3, it was suggested not to use the term GPS for other macrothrombocytopenia 
disorders that comprise abnormal α-granules numbers except for patients with NBEAL2 
defects. Important similarities indeed do exist (e.g. large platelets with paucity of α-granules, 
myelofibrosis, platelet dysfunction) but also important differences such as red cell 
abnormalities that are only described for GATA1 and GFI1B defects and the presence of 
CD34-positive platelets for GFI1B defects.  
In this study, we hypothesized that the α-granule defect found for GATA1 
macrothrombocytopenia might be due to reduced NBEAL2 expression. We compared platelet 
morphology and NBEAL2 protein expression using samples from two NBEAL2 and two 
GATA1-deficient macrothrombocytopenia patients. In vitro megakaryopoiesis from 
hematopoietic stem cells (HSC) from the GATA1 defective patients was studied with a focus 
on proplatelet formation, α-granule formation and NBEAL2 expression. Finally, ENCODE 
and GATA1/GATA2 ChIP sequencing data were used to predict putative enhancer elements 
upstream of the NBEAL2 gene. A long-distance (31 kb upstream) region was identified as 
potential enhancer that was characterized using reporter and DNA binding assays. 
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METHODS  
 
Patient studies 
Table 1 contains clinical and laboratory data for two previously described GATA113,14 
and two NBEAL2 deficient patients. Genetic screening of NBEAL2 was performed using a 
high-throughput sequencing test.19 Platelet testing and electron microscopy (EM) analysis was 
performed as described.13 The platelet surface area (μm2) and number of α-granules/μm2 were 
measured with ImageJ software. Patients or their legal representatives signed informed 
consent to participate in the enhanced clinical and laboratory phenotyping studies. The Ethics 
Committee of the University Hospitals Leuven approved the study (ref. ML3580). 
 
Megakaryocyte cultures, proplatelet formation and immunohistochemistry 
 CD34+ HSC were isolated from peripheral blood from patients with the GATA1 
D218Y and D218G variant and unrelated healthy controls. The MK differentiation assays and 
immunostainings are described in the supplement. Proplatelet-forming MK were analyzed as 
described.20,21  
 
Immunoblot analysis 
Proteins were isolated from platelets and in vitro differentiated MK as described.13 
Platelet extracts were also obtained from C57BL/6/GATA1 deficient mice (ΔneoΔHS), which 
have been described previously (Dr. Paresh Vyas, Department of Haematology and MRC 
Molecular Haematology Unit, Weatherall Institute of Molecular Medicine).22 Blots were 
performed as described in the supplements. 
 
Luciferase reporter assays to measure NBEAL2 enhancer activity 
The NBEAL2 enhancer region is located about 31 kb upstream of the NBEAL2 gene 
and within an intron of CCDC12 gene (GRCh37/hg19) and was cloned as two fragments 
being Chr3:46988756-46989716 (comprising 3 potential GATA sites BS-1-2-3) and 
Chr3:46989733-46990332 (comprising 2 potential GATA sites BS-4-5) in the pGL3 promotor 
(enhancer-less) vector (Promega). Details of cloning, mutagenesis, transfection of K562 cells 
and luciferase measurements are described in the supplements.23   
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Quantitative (q)RT-PCR to quantify GATA1, GATA2, NBEAL2, and ITGB3 expression 
Total RNA from K562 cells was extracted with TRIzol (Invitrogen). Expression of 
GATA1, GATA2, NBEAL2 and ITGB3 were measured with Sybr Green qRT-PCR using the 
ABI 7000 real-time PCR machine (Life Technologies). Expression was quantified via the 
ΔΔCt method in arbitrary units24 (see supplementary methods for primer details). 
 
DNA binding assay 
Biotinylated PCR fragments for BS-1-2-3 and BS-4-5 were bound to 
Superparamagnetic streptavidin beads (Hyglos) and added to NE isolated from HEK293 cells 
transfected with GATA1 or GATA2. The cloning, binding reaction, and blots are described in 
the supplements. 
 
GATA1 knockdown in K562 cells usin siRNA  
GATA1 depletion in K562 cells was obtained after transfection with SMARTpool 
GATA1 siRNA25 or negative control SMARTpool siRNA (Dharmacon) (see supplementary 
methods).  
 
Glutathione S-Transferase-pull down assay with GATA1-NF 
Glutathione S-Transferase (GST)-coupled GATA1-NF or GST-only bound to 
glutathione–sepharose beads (GE Healthcare) was prepared as described.13 
Immunoprecipitation was performed as described in the supplement. 
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RESULTS  
 
 
Clinical description and platelet morphology studies in macrothrombocytopenia 
patients with NBEAL2 and GATA1 variants 
 
Table 1 describes clinical and laboratory phenotypes for two GPS patients with 
recessive NBEAL2 variants and two boys with GATA1 variants. One GPS patient is 
homozygous for W2480X that is predicted to result in a non-functional protein without WD40 
domain (Figure 1A).  The other GPS patient has a homozygous splice variant c.5721-1G>C 
(Figure 1A), predicted to result in an early stop codon M1908X that would delete the PH, 
BEACH and WD40 domains. Indeed, a similar splice variant c.5720+1G>A in another GPS 
patient has been demonstrated to result in M1908X based on expression studies.27 The 
macrothrombocytopenia patients with GATA1 variants D218G13 and D218Y14 were 
previously described (Figure 1A). Both mutations are located in the N-terminal finger 
domain, which is required for association with the coactivator friend-of-GATA1 (FOG1) that 
contributes to stability of DNA binding to a palindromic GATA recognition sequence.28 
GATA1 D218Y resulted in a severe clinical phenotype with deep macrothrombocytopenia 
while patients with GATA1 D218G only have mild macrothrombocytopenia (Table 1). All 
patients have macrothrombocytopenia and blood smears and EM studies of their platelets 
clearly show a gray appearance of large platelets due to a paucity of α-granules. Myelofibrosis 
was present in the patient with NBEAL2 W2840X and the patient with GATA1 D218Y. Bone 
marrow studies observed the presence of megakaryocyte emperipolesis in all patients except 
the patient with the NBEAL2 M1908X variant. The platelet aggregation defect for the patient 
with NBEAL2 M1908X variant was similar to the defect found for the patient with GATA1 
D218G. The major difference between these cases is that the GPS patients have normal red 
blood cells while dyserythropoiesis was clearly present in GATA1 D218G13 and severe 
anemia with dyserythropoiesis in GATA1 D218Y.14 
Detailed morphological examination of platelets by EM for all patients was performed 
and compared. All have enlarged platelets that are more round instead of discoid with fewer 
α-granules and a pronounced open canalicular system forming large vacuoles in some 
platelets (Figure 1B). Quantification of the platelet size for three unrelated controls, two 
GATA1 and two NBEAL2 patients, showed significantly larger platelets in both patient 
groups. There was no difference between the patient groups (Figure 1C). The number of α-
granules corrected for platelet size showed a pronounced reduction for GATA1 patients and 
                      GATA1 controls NBEAL2 expression   
 
 8 
even more for the NBEAL2 patients that were now significantly different from GATA1 
patients (Figure 1D). 
 
Abnormal NBEAL2 expression in megakaryocytes from GATA1 patients 
 
Recent in vitro megakaryopoiesis studies using hematopoietic stem cells (HSC) from GPS 
patients with NBEAL2 mutations showed normal MK differentiation with defective 
proplatelet formation and reduced α-granule proteins such as VWF, thrombospondin and P-
selectin.29 Peripheral blood-derived HSC from GATA1 patients D218Y and D218G were 
differentiated to MK to quantify proplatelet formation during two independent culture 
experiments with each compared to another unrelated control. Similar as for NBEAL2 
deficiency, large MK were present but the MK for both patients showed significant decreased 
formation of proplatelets that was more pronounced for D218Y (Figure 2A). QRT-PCR was 
performed using RNA from MK at differentiation days 6 and 11 (for D218Y) or days 6 and 
13 (for D218G) (Figure 2B). NBEAL2 and ITGB3 were significant decreased throughout the 
MK differentiation for the GATA1 patients but again the defect was more pronounced for the 
D218Y patient. We performed immunoblot analysis using total protein lysates from 
differentiated MK to quantify NBEAL2 and integrin β3 expression. Remarkably, NBEAL2 
expression was absent in GATA1 D218Y compared to control MK at differentiation day 11 
(Figure 2C). As integrin β3 levels were also lower for GATA1 D218Y, we also loaded day 8 
differentiated MK from the control and these cells express comparable integrin β3 levels 
while NBEAL2 was clearly detectable. NBEAL2 expression was also studied at a later time 
point in MK differentiation (day 13) for GATA D218G but its expression remained low 
compared to control MK (Figure 2C). To exclude NBEAL2 degradation in GATA1 mutant 
MK, the expression of filamin (FLN), a large protein sensitive to calpain-mediated cleavage, 
was found to be comparable to control MK (Supplementary Figure S1).  
MK were stained at days 8 and 11 for VWF and actin to visualize α-granule formation 
(Figure 2D-E). During these final stages of megakaryopoiesis VWF staining was significantly 
reduced for GATA1 D218Y MK. These data could indicate that part of the similar MK and 
platelet phenotypes between NBEAL2 and GATA1 deficiency are due to the fact that GATA1 
is a transcription factor that drives NBEAL2 expression. 
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Strongly reduced NBEAL2 expression in GATA1-deficient platelets  
Immunoblot analyses were performed to compare NBEAL2 protein expression levels 
in platelets of patients with variants in GATA1 or NBEAL2 (Figure 3). Complete protein 
extracts of control platelets show a large protein that corresponds to full length NBEAL2 (302 
kDa) (Figure 3A, B). Platelets of the patient with the homozygous splice mutation that would 
result in the predicted M1908X showed strongly reduced, but not absent expression of full 
length NBEAL2. There was also the presence of a band with a lower molecular weight of 
about 150 kDa, that could represent a cleaved truncated product though we did not confirm 
this by mass spectrometry (Figure 3A, B). The homozygous W2480X NBEAL2 variant is 
predicted to result in a truncated protein of 27 kDa shorter than wild type NBEAL2, a small 
difference that is probably not detectable by gel electrophoresis of such a large protein. 
However, platelets from this patient clearly express very low NBEAL2 levels (Figure 3A, B). 
It is surprising to observe that platelets from the patients with the D218Y or D218G GATA1 
variants express no NBEAL2 (Figure 3A, B). An antibody for integrin β3 was used as loading 
control as we previously found that integrin β3 expression was relatively normal for GATA1-
deficient platelets using flow cytometry.13 NBEAL2 blots were performed with a rabbit 
polyclonal (Figure 3A, epitope against amino acids 1865-1939) and a rabbit monoclonal 
(Figure 3B; epitope against amino acids 1-100) NBEAL2 antibody with comparable results. 
Only for the patients with NBEAL2 W2480X and GATA1 D218Y sufficient platelet extract 
was available to triplicate the blots and quantify expression (Figure 3C). Quantification 
showed a marked decrease in NBEAL2 expression for platelets with the NBEAL2 W2480X 
variant while NBEAL2 was not detected in GATA1 D218Y deficient platelets. We also 
performed immunoblot analysis using total platelet extracts from hemizygous male and 
homozygous female GATA1-deficient mice and compared them to wild type mice (Figure 
3D, E). Equal amounts of integrin β3 positive platelet extracts were loaded. NBEAL2 was 
again strongly reduced for the GATA1-deficient mice that were previously described by 
others to display macrothrombocytopenia, defective megakaryopoiesis and reduced α-granule 
proteins in MK.22,30,31  
Female carriers of GATA1 variants are asymptomatic and our earlier studies revealed 
skewed X-inactivation and no mutant GATA1 RNA in platelets from the D218Y carrier while 
the D218G carrier had mild skewing of X-inactivation with the presence of the D218G 
mutation in platelet RNA.14 We also performed immunoblot analysis to compare NBEAL2 
protein expression in platelets of female carriers of GATA1 D218G and D218Y. Interestingly, 
no difference in NBEAL2 expression was found for D218Y while D218G carriers have 
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slightly lower levels of NBEAL2 (Supplementary Figure S2). This decrease in NBEAL2 
expression is not enough to cause a phenotype as these carriers have normal a platelet count 
and volume.13,14 To support the absence of protein degradation in these samples, blots were 
performed for FLN and GPIbα (Supplementary Figure S2).  
 
Identification of a long-distance NBEAL2 enhancer region 
 
GATA1 is an important transcription factor that binds the sequence WGATAR in 
regulatory elements of many genes important for erythropoiesis and megakaryopoiesis.32 Our 
data clearly show that GATA1 could regulate NBEAL2 expression and therefore, we have 
analyzed the NBEAL2 chromosomal region using ENCODE data.33 Figure 4A shows 
potential GATA1 and GATA2 binding sites (BS) that are present in the chromosomal 
NBEAL2 region. Interestingly, some of these BS are clustered in a region that is located 31 
kb upstream of the NBEAL2 gene within an intronic region of the nearby gene CCDC12 
(Chr3:46988970-46989880). This region is covered by an H3K4Me1 histone mark that is 
typically associated with an active enhancer. We only subtracted ChIP sequencing data from 
ENCODE that were determined for the myelogenous leukemia cell line K562 (in blue), 
known too express GATA1 and GATA234 and epidermal keratinocytes (NHEK in purple), 
included as non-blood cells. A H3K4Me3 mark covers the NBEAL2 promotor region that 
contains multiple GATA1 and GATA2 BS. The layered H3K27Ac track shows levels of 
enrichment of the H3K27Ac histone mark, which is often found near active regulatory 
elements and this peak overlaps the potential NBEAL2 enhancer. Chromatin interaction assay 
with paired end sequencing (or ChIA-PET) data for K562 cells further shows a physical 
interaction between this enhancer region and the NBEAL2 promotor (Figure 4A). The final 
lane displays the 100 vertebrates Basewise conservation by PhyloP. 
In addition, data were subtracted from a recent study that determined the genome-wide 
BS for the 5 key hematopoietic transcription factors GATA1, GATA2, RUNX1, FLI1, and 
TAL1/SCL in primary human MK.35 Interestingly, the NBEAL2 enhancer region is covered 
with ChIP sequencing peaks that are specific for GATA1 and GATA2 (Figure 4B). The exact 
location of these 2 peaks was also marked in figure 4A at the top panel. The first binding peak 
contains 3 potential GATA BS of which 2 have the reverted sequence (referred to as BS-1, 
BS-2, BS-3) while the 2nd peak contains 2 potential GATA BS (referred to as BS-4 and BS-5) 
(Figure 5A). 
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NBEAL2 enhancer activity using a luciferase reporter assay 
The two enhancer peaks were cloned as overlapping fragments (BS-1-2-3 and BS-4-5) 
in the pGL3 promotor vector to obtain luciferase reporter constructs (Figure 5A). PCR 
mutagenesis was used to obtain the following mutant luciferase reporter constructs:  BS-M1, 
BS-M2, BS-M3 and BS-M4-M5 that lack the GATA BS and will not bind GATA1/2 (Figure 
5A). We compared the enhancer activity of the different luciferase constructs in K562 that 
express high GATA1 and lower GATA2 levels (Figure 5B). Both enhancer fragments BS-1-2-
3 and BS-4-5 were able to significantly increase luciferase expression and mutagenesis of 
only GATA BS-2 and BS-3 blocked this enhancing activity. The mutants BS-1, BS-4 and BS-
5 did not significantly change the enhancing activity. The combination of BS-1-2-3 and BS-4-
5 showed a cumulative effect on the enhancer activity and the combination of BS-1-M2-3 and 
BS-M4-M5 blocked this enhancer activity (Figure 5C). 
 
DNA binding assay confirms binding of GATA to NBEAL2 enhancer 
We next performed a DNA binding assay using biotin-labelled DNA fragments that 
cover the two NBEAL2 enhancer peaks (again referred to as BS-1-2-3 and BS-4-5). These 
biotinylated DNA fragments bound to superparamagnetic streptavidin beads were incubated 
with nuclear extracts (NE) from GATA1 or GATA2 overexpressing HEK293 cells. The 
enhancer fragment BS-1-2-3 interacts with GATA1 and GATA2, but not with STAT5 for 
which there is no recognition site in the enhancer region (Figure 6A). Also the 2nd peak BS-4-
5 interacts strongly with GATA1 and GATA2 while mutagenesis of both GATA BS-4 and 
BS-5 in this fragment completely inhibits these interactions (Figure 6B). However, as 
mutagenesis of BS-4 and BS-5 did not change the enhancer activity (Figure 5C), these GATA 
sites might not be important for this enhancer region.  
 
siRNA mediated GATA1 depletion in K562 cells results in decreased NBEAL2  
We performed a GATA1 knockdown in K562 cells using SMARTpool GATA1 
siRNA and compared it to cells transfected with SMARTpool control siRNA (Figure 6B). 
After 24h, qRT-PCR showed a significant reduction in GATA1 expression while NBEAL2 
expression remained normal. However, after 48h a significant decreased NBEAL2 expression 
was observed. This was confirmed by immunoblot analysis using with strongly decreased 
NBEAL2 levels 48h after transfection (Figure 6C).  
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GATA1 binding to GFI1B 
FOG1 is known as a transcriptional co-regulator of GATA1 via interaction with its 
zinc fingers and the N-terminal GATA1 zinc finger (NF).13,14 We hypothesis that the zinc 
fingers of GFI1B might also interact with this NF GATA1 domain as a strong phenotype 
homology was noticed between GATA1 and GFI1B macrothrombocytopenia. Therefore, a 
pull down assay was performed that showed a physical interaction between the GATA1 NF 
and the large and short GFI1B isoform (Figure 6D). 
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DISCUSSION 
 
Important similarities, but also differences exist between clinical phenotypes caused 
by NBEAL2, GATA1 and GFI1B germline defects in humans.36 They share the presence of 
large platelets with α-granule defects, bone marrow fibrosis with presence of emperipolesis, 
platelet dysfunction and different degrees of bleeding. However, these diseases have a 
different mode of inheritance (recessive, X-linked and dominant for NBEAL2, GATA1 and 
GFI1B defects, respectively). More importantly, GATA1 and GFI1B, but not NBEAL2 
defects are characterized by red blood cell abnormalities and the severity of their α-granule 
defect is also different. Quantification of α-granule numbers for two NBEAL2 and two 
GATA1-deficient patients using EM indeed showed decreased α-granule numbers for all, but 
also a significant difference between both groups with almost no α-granules for NBEAL2 
defects. Nevertheless because of the important resemblance in the α-granule defect, we 
hypothesized that the transcription factor GATA1 could regulate NBEAL2 expression during 
megakaryopoiesis.  
Completely similar to the recent findings from Di Buduo et al29 who studied 
megakaryopoiesis using blood stem cells from GPS patients, stem cells from GATA1-
deficient patient showed normal MK differentiation, but a severe reduction in proplatelet 
formation with decreased α-granules. Abnormal MK maturation with severely impaired 
cytoplasmic maturation including fewer platelet-specific granules has been described for 
GATA1-deficient mice that lack an upstream regulatory region that controls Gata1 expression 
in MK.22,37 Moreover, reduced proplatelet and α-granule formation have also been described 
for V205G Gata1 transgenic mice that phenocopy patients with X-linked 
macrothrombocytopenia as this mutation blocks binding of the N-terminal GATA1 zinc 
finger (NF) to FOG1.38 The exact pathogenic mechanism of missense variants in GATA1 NF 
is not really understood but our previous in vitro binding assays with D218G and D218Y 
showed normal direct interaction with DNA and decreased interactions with FOG1.13,14 
However, more recent murine erythroid cell-based studies could only confirm the defective 
interaction between FOG1 and GATA1 D218Y while D218G was shown to interfere with the 
GATA1-TAL1 cofactor complex.39 If GATA1 D218G and D218Y are predicted to have 
different effects on DNA binding, they both resulted in abnormal NBEAL2 expression. 
Moreover, GATA1 depletion via deletion of a MK-specific enhancer in mice or using siRNA 
also resulted in decreased NBEAL2 expression. Therefore, our studies indicate that NBEAL2 
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expression can be regulated by changes in GATA1 levels or via functional changes in 
GATA1 NF. More studies are however needed to evaluate how these GATA1 NF variants 
could change direct or indirect DNA binding in gene promoters and enhancer regions. Also 
for GFI1B patients, bone marrow MK showed extensive peripheral cytoplasm with irregular 
proplatelets and being largely devoid of cell organelles12 while more recent in vitro 
differentiation assays with mutant GFI1B constructs in stem cells showed abnormal 
proplatelet formation.40 Further studies are needed to find if GATA1-GFI1B co-
transcriptional complexes could regulate NBEAL2 expression during megakaryopoiesis. 
To our knowledge, it was not yet known that NBEAL2 is a GATA1 target gene. 
GATA1 drives many important target genes for red blood cell and MK formation such as the 
globin genes, EPO, EPOR, GATA2, NFE2, GP1BA, GP1BB, PF4, MPL and some more.37,41 
Interestingly, a Bernard-Soulier syndrome patient with macrothrombocytopenia was 
described with a variant in the promoter of the GP1BB gene altering GATA1 binding together 
with a 22q11 deletion (involving GP1BB gene) on the other allele.42 This could mean that 
large platelets in GATA1 patients are due to defective GP1BB expression. This also 
implicates that the macrothrombocytopenia phenotype due to GATA1 deficiency is complex 
and can be the result of many genes that show aberrant GATA1-drive expression, but part of 
the overall phenotype and especially the α-granule defect could be due to NBEAL2 loss. 
Moreover, a long-distance enhancer region 31 kb upstream of the NBEAL2 gene was 
discovered in data from ENCODE for K562 cells that express high levels of GATA1 and 
whole genome ChIP sequencing data for GATA1 and GATA2 BS using primary MK (Figure 
4).35 Typical WGATAR recognition sequences (GATA1/2 BS) are present in this region and a 
physical interaction between this enhancer region and the NBEAL2 promoter was predicted 
based on ChIA-PET experiments using K562 cells.43 It is known that long-distance enhancers 
come into close proximity of target promoters through looping.44 Transcription factors and 
their complexes mediate such enhancer-promoter loop formation. The enhancer-gene loop is 
necessary for transcriptional up-regulation, but how the looping changes the transcriptional 
output is still unclear. Chromatin looping has been shown to be relevant for reactivation of 
globin genes45, but examples of such complex transcriptional regulation via interactions 
between enhancers and promoters important for gene expression during megakaryopoiesis 
remains largely unstudied. Insights in such mechanisms would be highly relevant to 
understand genome-wide association study findings that showed associations of mostly non-
coding variants with changes in platelet count and volume.46 It might therefore be that the 
non-coding variant influences expression of a long distance gene rather than the closest gene. 
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In this study, the NBEAL2 enhancer is actually located within an intron of another gene 
CCDC12 (Figure 4). We confirmed binding of GATA1 and GATA2 to this NBEAL2 
enhancer region with a DNA binding assay and showed that in luciferase reporter assays it 
functions as an enhancer element that depends mainly on GATA BS-2 and BS-3. Such GATA 
BS can of course be occupied by GATA1 or GATA2. GATA2 is essential for the 
maintenance of HSC and progenitor cells, whereas GATA1 drives the differentiation of HSC 
into megakaryopoiesis. GATA1 represses GATA2 transcription, and this involves GATA1 
mediated displacement of GATA2 from chromatin, a process that is called a GATA switch.47 
It is known that GATA switches play an important role in the differentiation of blood stem 
cells.48 Such a GATA switch can occur for the GATA BS in the enhancer of the NBEAL2 
gene and further studies are needed to unravel this exact mechanism as this might identify the 
exact moment that NBEAL2 is expressed during megakaryopoiesis. 
In conclusion, this study provides an explanation for the phenotypic resemblance 
between NBEAL2 and GATA1 defective macrothrombocytopenia with paucity of α-granules, 
as GATA1 is important for the NBEAL2 expression during megakaryopoiesis via a long-
distance enhancer. 
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Table 1. Comparison of clinical and laboratory data obtained for patients with defects in   
NBEAL2 and GATA1 
 
NBEAL2 
MIM13909 
GATA1 
MIM300367/314050 
Mode of inheritance Autosomal recessive X-linked 
Genetic defect Homozygous 
c.7440G>A 
Homozygous 
c.5721-1G>C c.653A>G  c.652G>T 
Protein defect  W2480X Predicted M1908X D218G D218Y 
 Dyserythropoiesis No Yes           Yes + anemia 
 Myelofibrosis  Yes            No No            Yes 
Macrothrombocytopenia Yes Mild TP Severe TP 
α-granule defect as 
determined by EM Yes Yes 
Megakaryotic 
emperipolesis Yes            ND Yes 
Plt count, x 109/L* 40 55 53 8 
MPV, fL > Max value > Max value > Max value > Max value 
Bleeding severity Mild to moderate Mild           Severe 
Platelet aggregation defect ND 
Performed at low 
plt count in PRP: 
Impaired ADP, 
collagen, 
arachidonic acid, 
and ristocetin-
induced plt 
aggregration 
Performed at 
low plt count in 
PRP: Impaired 
collagen, and 
ristocetin- 
induced plt 
aggregation 
ND 
Abbreviations: ND, not determined; EM, electron microscopy; Plt, platelet; MPV, mean platelet volume; PRP, 
platelet rich plasma; ADP, adenosine diphosphate; TP: thrombocytopenia. 
*Normal plt count should be between 150-400 x 109/L.  
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FIGURE LEGENDS  
 
Figure 1. Variants in NBEAL2 and GATA1 result in macrothrombocytopenia with a 
paucity of α-granules. (A) Schematic diagram displaying protein domains in the NBEAL2 
and GATA1 protein. The NBEAL2 protein contains an ARM-type fold, Con A-like lectin, 
PH, BEACH and WD40 domain. The NBEAL2 predicted M1908X and NBEAL2 W2480X 
variants are indicated. The GATA1 protein contains a transactivation domain (AD), N-
terminal finger domain (NF), and C-terminal finger domain (CF). Locations of the GATA1 
D218Y and D218G variants are indicated. Protein drawing is not to scale. AA; amino acids. 
(B) EM images of platelets for the 4 patients with different variants in comparison to an 
unrelated control show enlarged platelets that are more round instead of discoid with only a 
few α-granules and more open canalicular system forming vacuoles (Scale bars = 1μm). 
(C,D) The platelet area (μm2) and number of α-granules/μm2 were quantified. Values are the 
means ± SEM as quantified for two GATA1 patients, two NBEAL2 patients and three 
unrelated controls. The number of α-granules/μm2 showed a significant reduction for GATA1 
patients and even more pronounced reduction for the patients with NBEAL2 variants, which 
was significant compared to the patients with GATA1 variants. ***P < 0.001, ****P < 
0.0001, *P= 0.049, one-way analysis of variance (ANOVA) with Bonferroni’s multiple test. 
 
Figure 2. Effect of GATA1 D218Y and D218G variants on megakaryopoiesis.  
MK were differentiated from peripheral blood-derived CD34+ HSC from GATA1 patient 
D218Y, D218G and unrelated healthy controls. The MK differentiation assay was performed 
twice with different controls. (A) (Top) Proplatelet formation was quantified at day 11 or day 
13 of differentiation in duplicate liquid cultures for the control and the GATA1 patients. 
****P < 0.0001, t test. (Bottom) Proplatelet-forming MK were present in the control and in 
lesser extent in the GATA1 D218G (arrow). Though large MK were present for GATA1 
patient D218Y, proplatelet formation was not seen. (B) PCR data performed on RNA 
collected at day 6 and respectively day 11 or 13 from the D218Y and D218G defective MK. 
Expression levels of NBEAL2 and ITGB3 were normalised to GADPH expression. ****P < 
0.0001, t test. (C) Immunoblot analysis for NBEAL2 with a rabbit polyclonal antibody and 
integrin β3 were performed (left) using total protein MK lysates at days 8 and 11 for the 
control and day 11 for GATA1 D218Y (right) using total protein MK lysates at day 13 for 
the control and GATA1 D218G. (D, E) (Top) Representative immunofluorescence confocal 
microscopy images of differentiated MK at days 8 (D) and 11 (E) of culture. The MK were 
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stained for VWF (green) and actin (red). The control shows VWF factor present inside the α-
granules at day 8 with a further increase of VWF at day 11. The MK of GATA1 patient 
D218Y were only weakly positive for VWF both at day 8 and 11 (Scale bar =10μm). 
(Bottom) Quantification of VWF staining showed a significant reduction of VWF in GATA1 
D218Y patient at days 8 (D) and 11 (E) of culture in comparison to the control. Values are 
means ± SEM as quantified for 10 randomly selected images. *P < 0.05, panel C: day 8, 
*P=0.0465, t test; panel E: *P=0.0322, t test.   
 
Figure 3. NBEAL2 expression in GATA1 and NBEAL2-deficient platelets. 
 (A) Immunoblot analysis for NBEAL2 was performed with a rabbit polyclonal NBEAL2 
antibody (epitope against amino acids 1865-1939) for platelet lysates from patients with 
NBEAL2 M1908X, NBEAL2 W2480X, GATA1 D218Y and GATA1 D218G. Integrin β3 
was used as loading control. (B) Replicated immunoblots performed with a rabbit monoclonal 
NBEAL2 antibody (ab187162; epitope against amino acids 1-100) for platelet lysates from 
patients with NBEAL2 W2480X and GATA1 D218Y defect. Integrin β3 was used as loading 
control. (C) Quantification of NBEAL2 expression. **P=0.0077, ***P=0.0006, t test. (D, E) 
Expression of NBEAL2 in platelets from hemizygous male (D) and homozygous female (E) 
Gata1-deficient mice in comparison to sex matched wild type mice. For each lane platelets 
were pooled from 10 mice for Gata1 and 5 mice for control.  
 
Figure 4. Visualization of NBEAL2 enhancer with GATA binding peaks discovered by 
ChIP sequencing. 
 (A) Part of the CCDC12 gene is shown upstream of the NBEAL2 gene using the UCSC 
genome browser (chr3:46975201-47051622 using GRCh37/hg19). The upper layer shows the 
position of two NBEAL2 enhancer peaks within an intron of the CCDC12 gene. H3K4Me1, 
H3K4Me3 and H3K27Ac profiles for K562 (blue) and NHEK (purple) cell lines are displayed 
(data produced by Bernstein lab at Broad Institute as part of the ENCODE database).34 DNase 
Hypersensitivity 1 regions are displayed as gray to black boxes (from less to more open 
chromatin conformation). Transcription factor ChIP sequencing data are shown for GATA1 
and GATA2.36 A gray box encloses each peak cluster of transcription factors occupancy (with 
darkness of the box being proportional to the maximum signal strength). The ChIA-PET track 
shows the chromatin interaction in K562 cells determined by RNA polymerase II. Physical 
interaction is shown between the NBEAL2 enhancer and its promotor (ENCODE/GIS-Ruan). 
Conservation across vertebrates is displayed as blue histograms at the bottom of the figure 
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using the Vertebrate Multiz Alignment & Conservation (100 Species) UCSC track. (B) ChIP 
sequencing data (chr3:46988420-47051185) of primary human MK are shown in density plots 
and displayed in the UCSC genome browser beneath the tracks for gene structure. H3K4me3 
and H3K9Ac are visualized in the upper tracks (blue). GATA1 (purple) and GATA2 (pink) 
binding peaks are visualized in the bottom tracks. The NBEAL2 enhancer is located 
chr3:46988970-46989880). 
 
Figure 5. NBEAL2 enhancer activity using luciferase reporter assays. 
 (A) The binding peaks for GATA1 (purple) and GATA2 (pink) discovered by ChIP 
sequencing of primary human MK are visualized (ch3:46986830-46991970). Schematic 
overview of the location of the 5 potential GATA BS. BS-1-2-3 are located in the first peak 
and BS-4-5 in the second peak. The two fragments are cloned in a luciferase construct 3 
prime to the luciferase reporter gene to generate pGL3-BS-1-2-3 and pGL3-BS-4-5. BS 
mutants are pGL3-BS-M1-2-3, pGL3-BS-1-M2-3, pGL3-BS-1-2-M3 and pGL3-BS-M4-M5 
with the mutations indicated. (B) qRT-PCR for RNA from K562 was performed to determine 
the expression of GATA1 and GATA2 relative to GADPH. Expression was quantified via the 
ΔΔCt method in arbitrary units. (C) The luciferase expression after transfection with different 
constructs as indicated in K562 cells. The pGL3 promotor vector without enhancer sequence 
was used as control construct. Each plasmid was assayed in triplicate in six separate 
transfection experiments. ****P < 0.0001, one-way analysis of variance (ANOVA) with 
Bonferroni’s multiple test. 
 
Figure 6. DNA binding assays for NBEAL2 enhancer region with GATA1 and GATA2 
and the effect of GATA1 depletion on NBEAL2 expression.   
(A) DNA fragments BS-1-2-3 and BS-4-5 were labelled with biotin and bound to 
superparamagnetic streptavidin beads. NE were used from GATA1 or GATA2 
overexpression HEK293 cells. (left) Immunoblots for GATA1, GATA2 and STAT5 were 
performed on proteins bound to BS-1-2-3. STAT5 served as negative control. The unbound 
fraction is also shown. (Right) Immunoblots for GATA1 and GATA2 were performed on 
proteins bound to BS-4-5 and BS-M4-M5. GATA1 and GATA2 bind the wild type, but not 
the mutant DNA fragments. (B) qRT-PCR was performed on K562 cells with a GATA1 
siRNA depletion to determine the expression of GATA1 (left) and NBEAL2 (right) relative to 
GADPH after 24 and 48 hours. (left) **P=0.0073, t test; (right) ***P=0.0004, t test (C) (left) 
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Immunoblots analysis for NBEAL2 and integrin β3 on protein lysates collected after 48h. 
(Right) Quantification of NBEAL2 expression. **P=0.0050, t test.  
(D) Immunoprecipitation using GST-coupled GATA1-NF GST-beads and protein lysates 
from HEK293 cells transfected with the long and short GFI1B isoforms. These results are 
representative for three independent experiments. Control GST-beads (only GST sequence) 
and non-transfected (NT) HEK293 cells were used as negative controls.   
 






Supplementary	figures	and	methods	for	
The	transcription	factor	GATA1	regulates	NBEAL2	expression	
through	a	long-distance	enhancer	
	
Supplementary	figure	S1	
	
Figure	S1.	 Immunoblot	analysis	to	study	FLN	expression	 in	day	13	differentiated	MKs	from	
peripheral	blood-derived	CD34+	HSC	of	the	GATA1	D218G	patient	and	a	healthy	control.	No	
difference	in	expression	level	was	observed	and	no	evidence	for	increased	FLN	degradation	
in	the	D218G	sample	could	be	noticed.	
	
Supplementary	figure	S2.		
	
Figure	 S2.	 (A)	 Immunoblot	 analysis	 showed	 no	 significant	 difference	 in	 FLN	 and	 GPIBa	
expression	 levels	 between	 platelets	 of	 the	 GATA1	 D218G	 or	 D218Y	 female	 carriers	 and	
unrelated	controls.	No	degradation	bands	related	to	 these	proteins	were	observed	 for	 the	
carrier	 platelets.	 (B)	 Immunoblot	 analysis	 was	 performed	 to	 compare	 NBEAL2	 protein	
expression	 levels	 in	 platelets	 of	 GATA1	D218G	 or	D218Y	 female	 carriers.	 No	 difference	 in	
NBEAL2	 expression	 between	 the	 GATA1	 D218Y	 female	 carrier	 and	 control	 platelets	 was	
observed	while	female	carriers	with	GATA1	D218G	had	mildly	reduced	NBEAL2	levels	in	their	
platelets.	 We	 previously	 showed	 skewed	 X-inactivation	 and	 no	 mutant	 GATA1	 mRNA	 in	
platelets	 from	 the	 D218Y	 carrier	 while	 the	 D218G	 carrier	 had	 only	 weak	 skewing	 of	 X-
inactivation	with	the	presence	of	the	D218G	mutation	in	platelet	RNA	(4).	This	could	mean	
that	 the	 D218G	 GATA1	 mutation	 in	 her	 platelets	 resulted	 in	 slightly	 reduced	 NBEAL2	
expression.	 However,	 this	 mild	 reduction	 in	 NBEAL2	 seems	 not	 to	 have	 an	 effect	 on	 the	
phenotype	as	all	GATA1	female	carriers	have	normal	platelet	counts	and	no	clinical	bleeding	
symptoms	(2,4).	
	
	
Supplementary	figure	S3	
	
Figure	S3.	Uncropped	blots	for	Figure	2C	to	show	absence	of	NBEAL2	degradation	products	
in	the	D218G	and	D218Y	samples.	
	
	
Supplementary	figure	S4	
	
Figure	S4.	Uncropped	blots	for	the	different	panels	in	Figure	3.	
	
2.	SUPPLEMENTARY	METHODS		
	
Patient	studies	
The	NBEAL2	variants	will	be	deposited	in	the	LOVD	database	(under	submission).	The	
GATA1	 variants	 have	 already	 been	 deposited	 (ClinVar:		
http://www.ncbi.nlm.nih.gov/clinvar/variation/10427/	 for	 D218Y	 and	
http://www.ncbi.nlm.nih.gov/clinvar/variation/10424/	for	D218G).	
	
Megakaryocyte	cultures,	proplatelet	formation	and	immunohistochemistry	
The	MK	differentiation	assays	was	performed	twice	with	different	controls.	HSC	were	
cultured	in	StemSpan	SFEM	medium	(Stem	Cell	Technologies),	supplemented	with	20	ng/ml	
TPO,	 10	 ng/ml	 SCF,	 10	 ng/ml	 IL-6	 and	 10	 ng/ml	 FLT-3	 (Peprotech).	 Immunostaining	
experiments	 were	 performed	 at	 days	 8	 and	 11	 after	 incubation	 of	 MK	 for	 4	 hours	 on	
fibrinogen-coated	 coverslips.	 They	were	 performed	with	 anti-von	Willebrand	 factor	 (VWF)	
(A0082;	Dako)	and	an	Alexa	fluor	488-labelled	anti-rabbit	secondary	antibody	(Invitrogen)	in	
combination	 with	 Alexa	 Fluor	 594	 phalloidin	 (A12381;	 Life	 technologies).	 Microscopy	
pictures	 were	 taken	 at	 63x	magnifications	 with	 the	 Zeiss	 AxioVert	 200M	microscope	 and	
Zeiss	 Axiovision	 software.	 Quantification	 of	 the	 fluorescence	 signal	 was	 performed	 with	
ImageJ	software.		
	
Immunoblot	analysis		
The	 concentration	 of	 total	 protein	was	 determined	 by	 Bradford	 analysis	 and	 equal	
protein	fractions	(40µg)	were	resolved	by	SDS-PAGE	on	5%	acrylamide	gels	and	transferred	
to	 ECL-nitro-cellulose	membrane.	 The	 blots	 were	 blocked	 for	 1h	 at	 room	 temperature	 in	
Tris-buffered	saline	with	tween	(TBS-T;	0,1%	Tween-20)	supplemented	with	5%	non-fat	dry	
milk.	Blots	were	incubated	overnight	at	4°C	(the	dilution	for	all	antibodies	was	1:1000	in	1X	
TBS-T	 5%	 non-fat	 dry	 milk)	 with	 the	 following	 antibodies:	 rabbit	 polyclonal	 anti-NBEAL2	
(ab151150;	Abcam),	rabbit	monoclonal	anti-NBEAL2	(ab187162;	Abcam),	rabbit	monoclonal	
anti-GADPH	 (14C10;	 Cell	 Signaling),	 mouse	 polyclonal	 anti-Filamin	 (CP72;	 Calbiochem),	
mouse	 monoclonal	 anti-GPIBa	 (G27CG)	 (previously	 described4),	 and	 anti-integrin	 b3	 (sc-
14009;	 Santa	 Cruz	 Biotechnology).	 Blots	 were	 washed	 3	 times	 for	 10	min	 with	 1X	 TBS-T.	
Membranes	 were	 incubated	 with	 HRP-conjugated	 secondary	 antibodies	 (Dako)	 (dilution	
1:1000	in	1X	TBST	5%	nonfat	dry	milk)	for	2-3h	at	RT	and	staining	was	performed	with	ECL	
detection	 reagent	 (Life	 Technologies).	 Chemiluminescent	 blots	 were	 imaged	 with	 the	
ChemiDoc	MP	imager	(Bio-Rad)	and	ImageJ	software	was	used	for	densitometry	analysis.			
	
Luciferase	reporter	assays	to	measure	NBEAL2	enhancer	activity	
PCR	was	used	to	modify	the	5	potential	GATA	sites	and	are	referred	to	as	BS-M1-2-3,	
BS-1-M2-3,	BS-1-2-M3	(all	single	mutants)	and	a	double	mutant	BS-M4-M5.	The	primer	sets	
to	 clone	 the	 two	 different	 enhancer	 regions	 were:	 1)	 BS-1-2-3	 forward	 5’-
AGGAAGCTTAGTGTCACCTTGTGCCCATC-3’	 (HindIII	 site)	 and	 BS-1-2-3	 reverse	 5’-
CAGAAGCTTTGAGAACATCTGATAAG-3’	 (HindIII	 site)	 and	 2)	 BS-4-5	 forward	 5’-
GACTAGCTAGCAAGAGGCTGGGA-3’	 (NheI	 site)	 and	 BS-4-5	 reverse	 5’-
GGATCCCCGGGGACTTGGGCTGG-3’	(SmaI	site).	These	constructs	were	used	as	templates	for	
PCR	mutagenesis.	For	the	BS-M1-2-3	construct	BS-1-2-3	was	used	as	a	template.	The	primer	
sets	to	clone	the	pGL3-BS-M1-2-3	were	the	BS-1-2-3	forward	and	the	BS-M1-2-3	reverse	5’-
GTTCAGCTCACTTCTCAACACTCCATCTTC-3’	 together	 with	 the	 BS-M1-2-3	 forward	 5’-
CTGAAGATGGAGTGTTGAGAAGTGAGCTGAAC-3’	 and	 BS-1-2-3	 reverse.	 Those	 PCR	 products	
were	 combined	 to	 make	 the	 pGL3-BS-M1-2-3	 construct.	 The	 BS-1-2-3	 construct	 was	 also	
used	as	a	template	to	make	the	BS-1-M2-3	construct.	The	primer	sets	to	make	the	pGL3-BS-
1-M2-3	 were	 the	 BS-1-2-3	 forward	 and	 the	 BS-1-M2-3	 reverse	 5’-
TGGTCTGGTCAGCAGCTCGAGTGGATGCTCG-3’	 together	 with	 the	 BS-1-M2-3	 forward	 5’-
CGAGTATCCACTCTATCTGCTGACCA-3’	 and	 BS-1-2-3	 reverse.	 Those	 two	 PCR	 products	were	
also	 combined	 to	 create	 the	pGL3-BS-1-M2-3	 construct.	 To	make	 the	BS-1-2-M3	 construct	
the	BS-1-2-3	construct	was	used	as	template.	The	BS-1-2-3	forward	together	with	the	BS-1-2-
M3	reverse	primer	5’-CAGAAGCTTTGAGAAC	ATCTGAATAAG-3’was	used	to	create	the	BS-1-2-
M3	 construct.	The	pGL3	promotor	vector	without	enhancer	 sequence	was	used	as	control	
construct.	The	transfection	of	K562	cells	was	performed	with	the	Cell	line	nucleofector	Kit	V	
(Lonza)	using	the	Amaxa	electroporation	system	according	to	the	manufacturer's	instruction	
(method	 T016).	 pEGFP	 (Clontech)	 was	 added	 to	 the	 transfections	 to	 ensure	 equal	
transfection	efficiencies	as	done	before1.	 	Cell	extracts	were	prepared	after	48	hours	using	
1x	 reporter	 lysis	 buffer	 and	 40	 µl	 of	 cell	 extract	was	mixed	with	 50	 µl	 of	 luciferase	 assay	
reagent	 (Promega)	 to	 determine	 luciferase	 activity	 in	 a	 luminescence	 counter	 (EG&G	
Berthold	MicroLumat	Plus	LB96V)	as	described1,2.	Each	plasmid	was	assayed	 in	triplicate	 in	
six	separate	transfection	experiments.		
qRT-	PCR	to	quantify	GATA1,	GATA2,	NBEAL2	and	ITGB3	expression	
The	 GATA1	 forward	 5’-GATGAATGGGCAGAACAGGC-3’,	 GATA1	 reverse	 5’-
AGCTTGTAGTAGAGGCCGC-3’,	 GATA2	 forward	 5’-CCAAGTCCTCCGGTTCTTCC-3’,	 GATA2	
reverse	 primer	 5’-AGAGAGGGAAGCCAGAGGAG-3’,	 NBEAL2	 forward	 5’-
TCCTAGCCAGACTCCCAGAG-3’,	 NBEAL2	 reverse	 5’-CGCAATGGTGTTGAGTTGCA—3’,	 ITGB3	
forward	 5’-CGGTACGTGATATTGGTGAAGG-3’	 and	 ITGB3	 reverse	 5’-
AAACTCCTCATCACCATCCAC-3’	were	used.		
	
GATA1	knockdown	in	K562	cells	with	SiRNA		
GATA1	 depletion	 in	 K562	 cells	 was	 obtained	 after	 transfection	 with	 SMARTpool	
GATA1	 siRNA	 (Dharmacon)	 or	 negative	 control	 SMARTpool	 siRNA	 (Dharmacon).	 K562	 cells	
(10^6)	were	resuspended	 in	100µl	of	Nucleofector	solution	V	(Lonza)	and	transfected	with	
160	 pmol	 of	 SMARTpool	 GATA1	 siRNA	 (Dharmacon)	 or	 SMARTpool	 control	 siRNA	
(Dharmacon).	 This	 GATA1	 siRNA	was	 previously	 shown	 to	 be	 highly	 effective.5	 Cells	 were	
transfected	with	the	Nucleofector	II	(Lonza)	using	the	T-016	program	and	were	collected	at	
24h	 and	 48h	 post	 transfection	 for	 real	 time	 PCR	 and	 immunoblot	 analysis.	 qRT-PCR	 was	
performed	 to	 study	 expression	 of	GATA1	 and	NBEAL2	 and	 immunoblot	 analysis	 to	 detect	
protein	expression	of	NBEAL2	and	GADPH.	
	
DNA	binding	assay	
Biotynylated	 DNA	 fragments	 for	 the	 DNA	 binding	 assay	 were	 generated	 by	 PCR.	
Overlapping	 DNA	 fragments	 of	 980	 bp	 (for	 BS-1-2-3)	 and	 194	 bp	 (for	 BS-4-5)	 were	 PCR	
amplified	 using	 the	 following	 primer	 sets:	 	 biotin-labelled	 forward	 5’-
CATAGTGCCTGAAGGTGACAG-3’	 and	 biotin-labelled	 reverse	 primer	 5’-
ACTCTTGGTGAAGCACTGAA-3’	 for	 BS-1-2-3	 and	 forward	 primer	 5’-
GAACAGCGAGGCTAGAGATAAGGACTGGAGATAAGGACGG-3’	 and	 biotin	 labelled	 reverse	
primer	3’-CTCTTTGTCCCCTAAGTGCCA-5’	for	BS-4-5.	A	mutant	DNA	fragment	with	BS-M4-M5	
was	 also	 amplified	 by	 PCR	 using	 forward	 primer	 5’-
GAACAGCGAGGCTACTTGAGGACTGGACTTGAGGACGG-3’	 (mutant	 BS-4	 and	 BS-5	 are	
underlined)	and	a	biotin	labelled	reverse	primer	3’-CTCTTTGT	CCCCTAAGTGCCA-5’.	
The	 biotinylated	 PCR	 fragments	 were	 bound	 to	 Superparamagnetic	 streptavidin	 beads	
(Hyglos)	 and	 next	 added	 to	 NE	 isolated	 from	 HEK293	 cells	 transfected	 with	 pcDNA3.1	
containing	GATA1	or	GATA2.	This	binding	reaction	was	performed	with	50	µg	NE	and	1	µg	of	
Poly(dI-dc)	 (Thermo	Scientific)	 that	were	 added	 to	 1.5	µg	biotinylated	DNA	 for	 3	 hours	 at	
room	temperature.	Next	beads	were	washed	7	times	with	10xSSC	(1.5	M	Sodium	Chloride,	
0.15	M	 sodium	 citrate,	 pH	 7)	 to	 remove	 unbound	 DNA.	 After	 addition	 of	 loading	 buffer,	
samples	were	loaded	on	a	7%	SDS-PAGE.	The	blots	were	stained	with	anti-STAT5	(9363;	Cell	
Signaling),	 anti-GATA1	 (Sc-265;	 Santa	 Cruz	 Biotechnology)	 or	 anti-GATA2	 antibody	
(polyclonal	rabbit	antibody	previously	described3).	
	
Glutathione	S-Transferase-pull	down	assay	with	GATA1-NF	
Immunoprecipitation	 was	 performed	 in	 triplicate	 with	 GATA1-NF	 GST-beads	
incubated	with	total	protein	lysates	from	HEK293	cells	after	transfection	with	pWPT	(Trono	
lab,	Addgene)	containing	the	GFI1B	long	(NM_004188)	or	short	(NM_001135031)	isoform26	
using	 jetPRIME	 (Polyplus).	About	1	mg	of	HEK293	 lysate	was	added	 to	500	µl	RIPA	buffer,	
with	 GATA1-NF	GST	 or	 control	 GST	 beads	 for	 overnight	 incubation.	 After	 incubation	 and	
washing,	 the	 bound	 fraction	 was	 loaded	 on	 gel	 and	 immunoblots	 were	 performed	 with	
GFI1B	antibody	(sc-22795;	Santa	Cruz	Biotechnology).		
	
Statistical	analysis	
For	quantitative	assays,	treatment	groups	were	reported	as	mean	±SEM	and	
compared	using	the	unpaired	Student	t-test	and	one-way	analysis	of	variance	(ANOVA)	test	
with	Bonferroni’s	correction	using	Prism6	(GraphPad	Software	Inc.).	
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